summit 2014 September 28th - 30th Paris France Final programme Maison de la Chimie Meeting of the Working Group on Thrombosis European Society of Cardiology www.eurothrombosis-summit2014.org 14T2868_Eurothrombosis2014_programme_v2.indd 1 19/09/2014 17:23 Editorial COMMITTEES Organizing Committee COLLET Jean-Philippe (FR) HULOT Jean-Sébastien (FR) MONTALESCOT Gilles (FR) SILVAIN Johanne (FR) ON BEHALF OF THE WORKING GROUP on Thrombosis of the European Society of Cardiology, we are pleased to invite you to attend Eurothrombosis 2014. Working Group on Thrombosis CHAIRPERSON Prof. Robert Frederick Storey (UK), The Eurothrombosis delegates will be able to enjoy an exciting program in the VICE-CHAIRPERSON beautiful city of Paris. The Eurothrombosis meeting is organized annually and Dr Joao Morais (PT), is the official scientific meeting of the European Society of Cardiology´s working PAST-CHAIRPERSON group of thrombosis. The meeting 2014 will be of translational character with Prof. Dietrich C. L. Gulba (DE), lectures and symposia ranging from pre-clinical thrombosis research to clinical TREASURER trials and interventional cardiology. The program will address the most common Dr. Steen Husted (DK) clinical situations related to thrombo-cardiology but also novel fields including ORDINARY NUCLEUS MEMBERS microRNAs in cardiovascular diseases, from bench to clinic and the most recent Prof. Marco Cattaneo (IT), guidelines released during the ESC 2014 congress. Assoc. Prof. Sigrun Halvorsen, (NO), We encourage young clinicians and scientists to participate with oral presentations and poster sessions with opportunities to receive poster awards and travel grants. Prof. Gregory Y.H. Lip, FESC (GB), Assist.Prof. Bianca Rocca (AT), Dr Jurrien M. Ten Berg, FESC (NL), Prof. Ingebjorg Seljeflot, FESC (NO), Eurothrombosis 2014 will be held in the sumptuous Hotel Particulier of the Fon- Assoc. Prof. Thomas Weiss (AT), dation de la Maison de la Chimie located 28 rue Saint-Dominique. It was built Assoc. Prof. Johann Wojta (AT), in 1704 and was the residence of famous families including Tour d’Auvergne, EX-OFFICIO MEMBERS Caraman and Rochefoucauld Estissac until 1929. Located in the heart of the Prof. Jean-Philippe Collet (FR), main centers of institutional decisions and intellectual Paris Rive Gauche, this Prof. Agneta Siegbahn (SE), prestigious historic house is the scene of scientific events, cultural, political and Dr Felicita Andreotti (IT), economic, which by their content or media, make it live the rhythm of a news ASSOCIATE NUCLEUS MEMBERS constantly renewed. La Maison de la Chimie now summarizes the eighteenth Prof. Kurt Huber, FESC (AT), Inter and Art Deco styles. In very close vicinity you will find many of the most important Working Group liaison historic sites of Paris, with the Invalides, the Eiffel Tower, the prestigious Boule- Prof. Freek W. A. Verheugt, FESC vard Saint-Germain and Le Jardin des Tuileries with the Louvre just across the (NL), Newsflash editor Seine Rive. Eurothrombosis 2014 is compliant with the Eucomed Code of Ethical Business Practice, www.ethicalmedtech.eu. We look forward to welcoming you in Paris. Professor Jean-Philippe Collet Professor Jean-Sébastien Hulot Professor Gilles Montalescot Associate Professor Johanne Silvain 2 14T2868_Eurothrombosis2014_programme_v2.indd 2 19/09/2014 17:23 2014 Programme September 28th - 30th Paris France Maison de la Chimie SUNDAY, SEPTEMBER 28, 2014 09:00-10:00 _______________________________________ Discussion and audience interaction Registration Novel antithrombotic strategies in valvular diseases Jean-Philippe COLLET, Paris, FRANCE Welcoming Area 10:00-11:30 ________________________________________ Opening Plenary Lecture Amphithéâtre Lavoisier Chairs: Robert Frederick STOREY, Sheffield, U.K. - Joao MORAIS, Leiria, PORTUGAL Discussion and audience interaction Take-home message - Gilles MONTALESCOT, Paris, FRANCE 11:30-13:00 ________________________________________ Revascularization of stable coronary artery disease: for what benefit? Jean-Philippe COLLET, Paris, FRANCE Microparticles - Vascular cell sources and clinical implications Acute Coronary Syndrome: Have we reached the limits? Gilles MONTALESCOT, Paris, FRANCE Chairs: Agneta SIEGBAHN, Uppsala, SWEDEN - Nicolas AMABILE, Paris, FRANCE 11:30-13:00 ________________________________________ Microparticles - Circulating messengers in the cross - Talk of inflammation and thrombosis - Agneta SIEGBAHN, Uppsala, SWEDEN SYMPOSIUM BMS PFIZER Amphithéâtre Lavoisier Apixaban and Novel Oral Xa inhibitors in cardiology - Today and Tomorrow. With an unrestricted educational grant from BRISTOLMYERS-SQUIBB and PFIZER Room 101 Microparticles in metabolic syndrome and diabetes Lina BADIMON, Barcelona, SPAIN Microparticles in acute coronary syndromes - Biomarkers for longterm? - Nicolas AMABILE, Paris, FRANCE Chairman: Gilles MONTALESCOT, Paris, FRANCE Introduction and objectives - Gilles MONTALESCOT, Paris, FRANCE Apixaban for stroke prevention in non-valvular atrial fibrillation: new insights - Harald DARIUS, Berlin, GERMANY Discussion and audience interaction The atrial fibrillation patient with coronary artery disease Gilles MONTALESCOT, Paris, FRANCE Discussion and audience interaction 13:00-14:00 _______________________________________ Lunch Break and Poster Session 1 Exhibition Area 14:00-15:30 _______________________________________ Challenges in the management of atrial fibrillation patients Amphithéâtre Lavoisier Chairs: Kurt HUBER, Vienna, AUSTRIA - Robert Frederick STOREY, Sheffield, U.K. Anticoagulant strategies for elective cardioversion - Hector BUENO, Madrid, SPAIN ACTION Coeur is the first Academic Research Organization in France to initiate, develop, and conduct Academic trials related to strategic interventions or pharmaceutical or device interventions in collaboration with the Industry. ACTION Coeur is composed of engaged experts and scientific leadership within a large network of cardiac centers in France and Europe. ACTION Coeur has also developped a Core Laboratory and an imaging platform, Patient Educational Programs and Health Education Programs. ACCOAST - 2013 ATLAN TIC - 2 014 - 2012 ARCTIC Our vision for a healthcare e system organized around the patient perspective continues to be the driving force of ACTION Coeur For more information, you can visit us Stand NB 6 www.action-coeur.org https://twitter.com/ActionCoeur [email protected] Research Education Information 3 14T2868_Eurothrombosis2014_programme_v2.indd 3 19/09/2014 17:23 Programme SUNDAY, SEPTEMBER 28, 2014 16:00-17:30 _______________________________________ AFib at high bleeding risk: new drugs, not new devices! X. SPEAKER TO BE CONFIRMED Thrombus inhibition in the acute phase of ST-elevation myocardial infarction Amphithéâtre Lavoisier PRO - X. SPEAKER TO BE CONFIRMED CONTRA - Gilles MONTALESCOT, Paris, FRANCE Following drug-eluting stent, no more need for dual antiplatelet therapy on top of anticoagulation - Harald DARIUS, Berlin, GERMANY Chairs: Steen HUSTED, Herning, DENMARK - Johanne SILVAIN, Paris, FRANCE Changing anticoagulant - Gilles MONTALESCOT, Paris, FRANCE CONTRA - Nicolas DANCHIN, Paris, FRANCE GpIIb/IIIa still the most effective choice - Guillaume CAYLA, Nîmes, FRANCE 14:00-15:30 _______________________________________ Prasugrel versus Ticagrelor: is there a difference? - Mathieu KERNEIS, Paris, FRANCE Using biology to inform treatment Cangrelor is the future - Sergio LEONARDI, Pavia, ITALY PRO - Erik Lerkevang GROVE, Aarhus, DENMARK Room 101 Chairs: Marco CATTANEO, Milan, ITALY - Johann WOJTA, Vienna, AUSTRIA High-sensitivity troponin: will cardiology ever be the same again? Patrick RAY, Paris, FRANCE 16:00-17:30 _______________________________________ Important clinical aspects in antithrombotic therapy Room 101 Chairs: Robert Frederick STOREY, Sheffield, U.K., X. CHAIRMAN TO BE Can platelet function testing make a difference? Guillaume CAYLA, Nîmes, FRANCE CONFIRMED What can functional genomics tell us? - Jean-Sébastien HULOT, Paris, FRANCE Antidotes for new anticoagulants - Marco CATTANEO, Milan, ITALY Assays for new anticoagulants - Ludovic DROUET, Paris, FRANCE How can we use stress biomarkers to inform treatment decisions? Patrick RAY, Paris, FRANCE 15:30-16:00 _______________________________________ Coffee break and Poster Session 2 Exhibition Area How to manage acute bleeding or overdose - Peter CLEMMENSEN, Copenhagen, DENMARK Platelet function testing: finding the optimal time for surgery Elisabeth MAHLA, Graz, AUSTRIA Pre-operative strategies in patients referred for CABG - Kurt HUBER, Vienna, AUSTRIA Direct Oral Anticoagulants in AF Patients undergoing Cardiac Intervention Satellite Symposium supported by Bayer HealthCare 4 14T2868_Eurothrombosis2014_programme_v2.indd 4 Monda y 29 Sep tem b 11:30 – er 2014 13:00 Amphi thê Lavoisi atre er G.GM.XA.08.2014.0423 © Bayer HealthCare Pharmaceuticals September 2014 19/09/2014 17:23 2014 September 28th - 30th Paris France Maison de la Chimie MONDAY, SEPTEMBER 29, 2014 08:00-09:30 ______________________________________ 10:00-11:30 ________________________________________ MicroRNAs and long non coding RNAs in cardiovascular medicine Antithrombotic treatment options in venous thromboembolism Amphithéâtre Lavoisier Room 101 Chairs: Agneta SIEGBAHN, Uppsala, SWEDEN - Gemma VILAHUR, Barcelona, SPAIN Chairs: Steen HUSTED, Herning, DENMARK - Bianca ROCCA, Rome, ITALY Small or long non coding RNAs? - Thierry PEDRAZZINI, Lausanne, SWITZERLAND Individualized oral anticoagulant therapy in VTE? - Joao MORAIS, Leiria, PORTUGAL The role of microRNAs in angiogenesis - Johann WOJTA, Vienna, AUSTRIA Treatment of VTE in cancer patients - Emmanuel MESSAS, Paris, FRANCE Hypoxia-inducible MicroRNAs - Fabio MARTELLI, Rome, ITALY Time for catheter-directed thrombolysis in acute deep vein thrombosis? - Per Morten SANDSET, Oslo, NORWAY MicroRNAs therapeutic strategies for vascular diseases Xavier LOYER, Paris, FRANCE Treatment duration in VTE-use of clinical or biochemical markers? Steen HUSTED, Herning, DENMARK 08:00-09:30 ______________________________________ 11:30-13:00 ________________________________________ Academic studies to change practice (ACTION Session) Room 101 Supported with an unrestricted educational grant from AstraZeneca Chairman: Gilles MONTALESCOT, Paris, FRANCE The CYP2C19 story: from registries to ARCTIC - Guillaume CAYLA, Nîmes, FRANCE SYMPOSIUM BAYER HEALTHCARE Oral anticoagulants in AF patients undergoing cardiac intervention Amphithéâtre Lavoisier Chairman: Jean-Philippe COLLET, Paris, FRANCE Introduction and objectives - Jean-Philippe COLLET, Paris, FRANCE The IV enoxaparin story: from dose finding studies to ATOLL Johanne SILVAIN, Paris, FRANCE Anticoagulant strategies in AF with CAD - Steen HUSTED, Herning, DENMARK The Aldosterone story: from old data to ALBATROSS Gilles Montalescot, Paris, FRANCE Anticoagulant strategies with PCI in ACS patients - Freek VERHEUGT, Amsterdam, NETHERLANDS The TAVI story: from no data to ATLANTIS - Jean-Philippe COLLET, Paris, FRANCE Anticoagulant strategies in patients undergoing EP intervention Ricardo CAPPATO, San Donato Milanese, ITALY Gene therapy in heart failure: from bench to AGENT Jean-Sébastien HULOT, Paris, FRANCE Discussion 09:30-10:00 _______________________________________ 11:30-13:00 ________________________________________ Coffee break and Poster Session 3 Transfusion in ACS Concluding remarks - Jean-Philippe COLLET, Paris, FRANCE Exhibition Area Room 101 10:00-11:30 ________________________________________ Chairs: Raffaele DE CATERINA, Chieti, ITALY - Sigrun HALVORSEN, Oslo, NORWAY Pretreatment with antiplatelet therapy in PCI RBC transfusion: impact on platelets and inflammation Johanne SILVAIN, Paris, FRANCE Amphithéâtre Lavoisier Chairs : Erik Lerkevang GROVE, Aarhus, DENMARK - Adeel SHAHZAD, Liverpool, U.K. Bleeding or transfusion: what is worse? - Johanne SILVAIN, Paris, FRANCE Pre-treatment with P2Y12 inhibitors in elective PCI Anne BELLEMAIN-APPAIX, Antibes, FRANCE Liberal or conservative strategy for transfusion? Etienne PUYMIRAT, Paris, FRANCE Pre-treatment with P2Y12 inhibitors in NSTE-ACS Gilles MONTALESCOT, Paris, FRANCE Platelet transfusion: does it work? - Stephen O’CONNOR, U.K. Pre-treatment with P2Y12 inhibitors in STEMI Robert Frederick STOREY, Sheffield, U.K. 13:00-14:00 _______________________________________ Lunch break and Poster Session 4 Exhibition Area 13:15-14:00 ________________________________________ Young Thrombosis Researchers Group General Assembly Room 101 5 14T2868_Eurothrombosis2014_programme_v2.indd 5 19/09/2014 17:23 Programme MONDAY, SEPTEMBER 29, 2014 14:00-15:30 _______________________________________ SYMPOSIUM BOEHRINGER INGELHEIM Atrial fibrillation: Heart and brain Amphithéâtre Lavoisier Chairs: Jean-Philippe COLLET, Paris, FRANCE - Gregory Y.h. LIP, Birmingham, U.K. Introduction - Jean-Philippe COLLET, Paris, FRANCE My patient on a oral anticoagulant needs an ablation or device implantation - Xavier WAINTRAUB, Rennes, FRANCE Do we still need antiplatelet therapy? The aspirin conspiracy Raffaele DE CATERINA, Chieti, ITALY 16:00-17:30 _______________________________________ The sweet, the fat and the cardiovascular system (ICAN Session) Management of stroke-risk in patients with AF and ACS: the RE-DUAL PCI trial - Gregory Y.h. LIP, Birmingham, U.K. Uninterrupted anticoagulant treatment in patients with AF who undergo ablation: the RE-CIRCUIT trial - Richard SCHILLING, London, U.K. A potential antidote for patients taking Pradaxa® who have uncontrolled bleeding or require emergency procedures: the REVERSE-AD trial - Joanne VAN RYN, Baden-Württemberg, GERMANY Room 101 Chairs: Ingebjorg SELJEFLOT, Oslo, NORWAY - Robert Frederick STOREY, Sheffield, U.K. Perivascular fat and atherosclerosis - Charalambos ANTONIADES, Oxford, U.K. Fifty shades of brown: redefining the adipose tissue Benedicte GABORIT, Paris, FRANCE Insulin resistance, hyperglycemia and atherosclerosis Ingebjorg SELJEFLOT, Oslo, NORWAY Questions & Answers Closing and summary - Gregory Y.h. LIP, Birmingham, U.K. Glitazones: a failure story? - Franck BOCCARA, Paris, FRANCE 14:00-15:30 _______________________________________ PCSK9: a success story? - David ROSENBAUM, Paris, FRANCE New delivery devices Nanomedicine and new particles 17:30-18:30 _______________________________________ Room 101 Chairs: Johann WOJTA, Vienna, AUSTRIA - Jean-Sébastien HULOT, Paris, FRANCE New vectors for vascular gene transfer - Andrew H. BAKER, Glasgow, U.K. Nanosystem for imaging of thrombus - Didier LETOURNEUR, Paris, FRANCE Magnetic Nanoparticles for molecular imaging of the plaque Marc SIROL, Paris, France Nanotechnology to diagnose and treat the atherosclerotic plaque X. SPEAKER TO BE CONFIRMED Dual antiplatelet therapy after stenting Amphithéâtre Lavoisier Chairs: Robert Frederick STOREY, Sheffield, U.K.- Gilles MONTALESCOT, Paris, FRANCE Six months are enough: Pro - Adeel SHAHZAD, Liverpool, U.K. Six months are enough: Contra - Stephan JAMES, Uppsala, SWEDEN Interruption studies are biased? - Freek VERHEUGT, Amsterdam, NETHERLANDS Rationale and design of the GLOBAL LEADERS trial - Kurt HUBER, Vienna, AUSTRIA 17:30-18:30 _______________________________________ 15:30-16:00 _______________________________________ Coffee break and Poster Session 5 Exhibition Area 16:00-17:30 _______________________________________ SPONSORED SESSION DAIICHI SANKYO EUROPE Practical aspects on stroke prevention in atrial fibrillation. What to do in 2014? Amphithéâtre Lavoisier Difficult situations in ACS management Room 101 Chairs: Jean-Philippe COLLET, Paris, FRANCE - Sigrun HALVORSEN, Oslo, NORWAY Challenging the guidelines: how to treat shock patients? Holger THIELE, Lübeck, GERMANY Hypothermia in cardiac arrest: for whom and when? Nicolas BRECHOT, Paris, FRANCE Chairs: Gregory Y.h. LIP, Birmingham, U.K. - Jean-Philippe COLLET, Paris, FRANCE Immediate coronary angiography in cardiac arrest patients: for selected patients or for all? - Christian SPAULDING, Paris, FRANCE My patient with AF has had a previous intracranial bleeding event Sonia ALAMOVITCH, Paris, FRANCE Assist devices: indications and choice - Pascal LEPRINCE, Paris, FRANCE My patient on a oral anticoagulant presents with an ischaemic stroke, and is being considered for thrombolysis - Yves SAMSON, Paris, FRANCE 19:00-19:30 _______________________________________ Wine and Jazz Exhibition Area 6 14T2868_Eurothrombosis2014_programme_v2.indd 6 19/09/2014 17:23 2014 September 28th - 30th Paris France Maison de la Chimie TUESDAY, SEPTEMBER 30, 2014 08:00-09:30 ______________________________________ 10:00-11:30 ________________________________________ Long-term anticoagulation after an ACS Amphithéâtre Lavoisier Best abstracts and young investigators session Chairs: Dietrich GULBA, Oberhausen, GERMANY - Freek VERHEUGT, Amsterdam, NETHERLANDS Chairman : Gemma VILAHUR, Barcelona, SPAIN - Joao MORAIS, Leiria, PORTUGAL Warfarin in combination with antiplatelet therapy - Steen HUSTED, Herning, DENMARK NOACs in combination with antiplatelet therapy Raffaele DE CATERINA, Chieti, ITALY O-01 The platelet receptor P2Y12 gene polymorphisms could predict bleedings in patients with ST-elevation myocardial infarction after percutaneous coronary intervention - Jia-Hui ZHANG, Beijing, CHINA Management of antithrombotic strategies after bleeding Sigrun HALVORSEN, Oslo, NORWAY O-02 Hyperglycaemia reduces the antiplatelet effect of aspirin Søs NEERGAARD-PETERSEN, Aarhus, DENMARK Where to go from now on? - Dirk SIBBING, Munich, GERMANY O-03 Female sex as a risk factor for thromboembolism and death in patients with incident atrial fibrillation - The Danish Diet, Cancer and Health study - Thure Filskov OVERVAD, Aalborg, DENMARK 08:00-09:30 ______________________________________ Development in antithrombotic strategies Room 101 Chairs: Kurt HUBER, Vienna, AUSTRIA - Joao MORAIS, Leiria, PORTUGAL Pre-hospital antithrombotic strategies in NTSEMI - Worth organizing? Johanne SILVAIN, Paris, FRANCE Pre-hospital antiplatelet and anticoagulation in STEMI - MULTIPRAC registry update - Peter CLEMMENSEN, Copenhagen, DENMARK Bivalirudin in Acute Coronary Syndromes - Update 2014 Adeel SHAHZAD, Liverpool, U.K. O-05 Lower mortality and stent thrombosis rates associated with introduction of potent P2Y12 inhibitors in patients with acute coronary syndromes - Rebecca ROWE, Sheffield, U.K. O-06 High incidence of stent thrombosis after percutaneous coronary intervention in patient survivors of out-of-hospital cardiac arrest - Guillaume GOUFFRAN, Paris, FRANCE Antiplatelet therapy in patients with coronary stent undergoing surgery 09:30-10:00 _______________________________________ Exhibition Area 10:00-11:30 ________________________________________ Hot topic in STEMI interventions O-04 Ticagrelor and clopidogrel modify human immune responses in-vivo - Mark THOMAS, Sheffield, U.K. 11:30-13:00 ________________________________________ Cangrelor and Vorapaxar - Promises for the future? Robert Frederick STOREY, Sheffield, U.K. Coffee break and Poster Session 6 Room 101 Amphithéâtre Lavoisier Amphithéâtre Lavoisier Chairs: Jean-Philippe COLLET, Paris, FRANCE - Erik Lerkevang GROVE, Aarhus, DENMARK Recognizing the risks - Joao MORAIS, Leiria, PORTUGAL Antiplatelet therapy: to bridge - Pro - Dietrich GULBA, Oberhausen, GERMANY Chairs : Freek VERHEUGT, Amsterdam, NETHERLANDS Robert Frederick STOREY, Sheffield, U.K. Antiplatelet therapy: to bridge - Contra - Steen HUSTED, Herning, DENMARK Upstream versus intraprocedural antiplatelet therapy Jean-Philippe COLLET, Paris, FRANCE Recommendations from the 2014 ESC Guidelines - Bernard IUNG, Paris, FRANCE Multivessel PCI - Dirk SIBBING, Munich, GERMANY Mechanical thrombectomy - Addel SHAHZAD, Liverpool, U.K. Intra-aortic balloon pump - Christian SPAULDING, Paris, FRANCE 7 14T2868_Eurothrombosis2014_programme_v2.indd 7 19/09/2014 17:23 Programme TUESDAY, SEPTEMBER 30, 2014 11:30-13:00 ________________________________________ 14:00-15:30 _______________________________________ New targets in atherothrombotic disease: thinking outside the box CLOSING CEREMONY - Keynote Lecture Room 101 Chairs : Johann WOJTA, Vienna, AUSTRIA - Gemma VILAHUR, Barcelona, SPAIN Targeting soluble epoxide hydrolase - Jeremy BELLIEN, Rouen, FRANCE Targeting vascular glycocalyx - X. SPEAKER TO BE CONFIRMED Targeting interleukin 1 receptor - X. SPEAKER TO BE CONFIRMED Targeting von Willebrand factor - Bernd JILMA, Vienna, AUSTRIA 13:00-14:00 _______________________________________ Lunch break Exhibition Area Amphithéâtre Lavoisier Chairs: Jean-Philippe COLLET, Paris, FRANCE - Raffaele DE CATERINA, Chieti, ITALY Mechanisms of thrombogenesis in cardiovascular disease: insights from arterial and venous thrombosis - Agneta SIEGBAHN, Uppsala, SWEDEN Clinical assessment of stroke and bleeding risk in atrial fibrillation: from evidence to guidelines - Gregory Y.h. LIP, Birmingham, U.K. Young Thrombosis Researchers Group, Lab exchange grants Announcement of awardees - Erik Lerkevang GROVE, Aarhus, DENMARK 15:30 _____________________________________________ End of Conference Amphithéâtre Lavoisier Angiox is indicated as an anticoagulant in adult patients undergoing percutaneous coronary intervention (PCI), including patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI. Angiox is also indicated for the treatment of adult patients with unstable angina/non-ST segment elevation myocardial infarction (UA/NSTEMI) planned for urgent or early intervention. Angiox should be administered with aspirin and clopidogrel. 8 14T2868_Eurothrombosis2014_programme_v2.indd 8 Full prescribing information is available at the stand. 19/09/2014 17:23 AP 2014 September 28th - 30th Paris France Maison de la Chimie 9 AP DAIICHI 210x297 sept14 GB.indd 1 14T2868_Eurothrombosis2014_programme_v2.indd 9 04/09/14 16:13 19/09/2014 17:23 General information Monday 29th September: from 7:00 am to 6:30 pm Congress venue Maison de la Chimie 28bis rue Saint-Dominique 75007 Paris, France Tuesday 30th September: from 7:30 am to 3:30 pm • Plenary Sessions Amphithéâtre Lavoisier, level 1 Room 101, level 1 Social programme Wine and jazz, Monday 19:00-19:30 Room 8, level 0 • Preview Room Room 131, level 1 Useful information • Coffee break and lunch buffet Room 8, level 0 Train: www.sncf.fr Plane: www.aeroportsdeparis.fr • Exhibition & poster area Room 8, level 0 Opening hours The Registration area and the Preview room will open: Sunday 28th September: from 9:00 am to 5:30 pm AKNOWLEDGEMENT Access: Public transport: timetables and lines available on www.ratp.fr The closest stations to the Maison de la Chimie are: Metro: Line 8 and 13 (Invalides station), Line 12 (Assemblée Nationale station) RER: Line C (Esplanade des Invalides) Bus: Bus 69 (Esplanade des Invalides) Bus 63, 73, 83,84, 94 (Assemblée Nationale station) Tourist information Office du Tourisme et des Congrès de Paris 25 Rue des Pyramides, 75001 Paris, France http://en.parisinfo.com Contact 19, allées Jean Jaurès – BP 61508 31015 Toulouse – France Email : [email protected] The Organizing Committee would like to thank all partners for their support Platinium Partners Gold Partners Silver Partners Bronze Partners Partner 10 14T2868_Eurothrombosis2014_programme_v2.indd 10 19/09/2014 17:23 2014 September 28th - 30th Paris France Maison de la Chimie 11 14T2868_Eurothrombosis2014_programme_v2.indd 11 19/09/2014 17:23 OPTIMIZING PATIENT PROTECTION Novel trials and new horizons with NOACs Monday 29 September 2014, 14:00–15:30 Amphithéâtre Lavoisier Programme Co-Chairs: Jean-Philippe Collet Gregory Lip Welcome and introduction Management of stroke-risk in patients with AF and coronary disease Jean-Philippe Collet Gregory Lip Periprocedural anticoagulation in patients with AF who undergo ablation Richard Schilling Update on strategies for the reversal of NOACs Joanne Van Ryn Q&A Summary and close All Gregory Lip A satellite symposium to be held at Eurothrombosis 2014, 28–30 September, Paris, France 14T2868_Eurothrombosis2014_programme_v2.indd 12 600949 Eurothrombosis A4 Ad.indd 1 19/09/2014 09/09/2014 17:23 11:45
© Copyright 2024 ExpyDoc
